|
rs861539
|
|
|
0.070 |
GeneticVariation |
BEFREE |
XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
|
24116196 |
2013 |
|
rs861539
|
|
|
0.070 |
GeneticVariation |
BEFREE |
XRCC3 Thr241Met played an opposite role in predicting prognosis of chemotherapy in NSCLC patients according to the first-line regimens.
|
22374424 |
2012 |
|
rs13181
|
|
|
0.100 |
GeneticVariation |
BEFREE |
XPD Lys751Gln (A>C) may have inverse predictive and prognostic role in platinum-based treatment of NSCLC according to different ethnicities.
|
24260311 |
2013 |
|
rs2228001
|
|
|
0.010 |
GeneticVariation |
BEFREE |
XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
|
22166526 |
2010 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With the advent of third generation TKIs that potentially target T790M, improvement in clinical outcome is documented in patients with NSCLCs.
|
28642172 |
2017 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
With limited treatment options available in this setting, osimertinib is an important option in adult patients with advanced EGFR T790M-positive NSCLC.
|
28710746 |
2017 |
|
rs6953668
|
|
|
0.010 |
GeneticVariation |
BEFREE |
With an aim to determine the association of variations in <i>IGF2BP2</i> and <i>IGFBP3</i> genes with risk of non-small-cell lung cancer (NSCLC), <i>IGF2BP2</i> rs1470579 A>C, rs4402960 G>T and <i>IGFBP3</i> rs2270628 C>T, rs3110697 G>A, and rs6953668 G>A polymorphisms were selected and genotyped in 521 NSCLC patients and 1,030 controls.
|
30214291 |
2018 |
|
rs3110697
|
|
|
0.010 |
GeneticVariation |
BEFREE |
With an aim to determine the association of variations in <i>IGF2BP2</i> and <i>IGFBP3</i> genes with risk of non-small-cell lung cancer (NSCLC), <i>IGF2BP2</i> rs1470579 A>C, rs4402960 G>T and <i>IGFBP3</i> rs2270628 C>T, rs3110697 G>A, and rs6953668 G>A polymorphisms were selected and genotyped in 521 NSCLC patients and 1,030 controls.
|
30214291 |
2018 |
|
rs2270628
|
|
|
0.010 |
GeneticVariation |
BEFREE |
With an aim to determine the association of variations in <i>IGF2BP2</i> and <i>IGFBP3</i> genes with risk of non-small-cell lung cancer (NSCLC), <i>IGF2BP2</i> rs1470579 A>C, rs4402960 G>T and <i>IGFBP3</i> rs2270628 C>T, rs3110697 G>A, and rs6953668 G>A polymorphisms were selected and genotyped in 521 NSCLC patients and 1,030 controls.
|
30214291 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While no significant difference in OS was observed between EGFR exon 19 deletion and L858R mutation, EGFR exon 19 deletion was predictive of longer PFS following EGFR TKI treatment in patients with advanced NSCLC.
|
21725039 |
2011 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While no significant difference in OS was observed between EGFR exon 19 deletion and L858R mutation, EGFR exon 19 deletion was predictive of longer PFS following EGFR TKI treatment in patients with advanced NSCLC.
|
21725039 |
2011 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
While no significant difference in OS was observed between EGFR exon 19 deletion and L858R mutation, EGFR exon 19 deletion was predictive of longer PFS following EGFR TKI treatment in patients with advanced NSCLC.
|
21725039 |
2011 |
|
rs141726378
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs1622002
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs60718122
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs751648572
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs4680
|
|
|
0.020 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs754845817
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs759684602
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs781598341
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs10012
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When we corrected for multiple testing using these statistical tools, three novel associations of NSCLC risk with SNPs in the CYP1B1 (Arg48Gly), COMT (Val158Met) and GSTT2 (Met139Ile) genes were found noteworthy.
|
18258609 |
2008 |
|
rs7041
|
|
|
0.040 |
GeneticVariation |
BEFREE |
When studies were stratified by cancer type, our results indicated that rs4588 significantly increased the risk of breast cancer and digestive system tumor, but not in prostate cancer and non-small cell lung cancer, while rs7041 significantly increased the risk of non-small cell lung cancer.
|
31467173 |
2019 |
|
rs4588
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When studies were stratified by cancer type, our results indicated that rs4588 significantly increased the risk of breast cancer and digestive system tumor, but not in prostate cancer and non-small cell lung cancer, while rs7041 significantly increased the risk of non-small cell lung cancer.
|
31467173 |
2019 |
|
rs6822976
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified by smoking status, the decreased risk of NSCLC was observed to be associated with the genotype with at least one rs6822976 G allele among non-smokers (OR = 0.66; 95% CI = 0.47-0.93), but not among smokers (OR = 1.01; 95% CI = 0.67-1.53).
|
25394898 |
2015 |
|
rs7671905
|
|
|
0.010 |
GeneticVariation |
BEFREE |
When stratified by age, we found that rs7671905 TT genotype has contributed to the decreased risk of N</span>SCL</span>C among older subjects with OR (95% CI) of 0.46 (0.23-0.95), but not among younger subjects with OR (95% CI) of 0.64 (0.31-1.34) (P(interaction) = 0.03).
|
25394898 |
2015 |